Sunfun Info held its annual shareholders’ meeting on June 26, chaired by Chairman Chia-Ming Chang, where it approved a fourth-quarter 2024 dividend distribution of NT$0.2036 per share in cash. To strengthen working capital and support future investments in new ventures—particularly in AI and the beauty & housing sectors—the company plans to issue both cash and stock dividends in parallel. Meanwhile, on June 25, its subsidiary Daiken Biomedical received formal approval for its initial public offering from the Taiwan Stock Exchange Board of Directors.
Sunfun reported consolidated revenue of NT$221 million in May, a year-on-year increase of 33.5%, and cumulative revenue of NT$948 million for the first five months of the year, marking a new record for the same period. This growth has been driven by continued optimization and deepening market penetration of its dating platform services, alongside steady expansion in its health and nutrition business. Apps such as iPair, SweetRing, and weTouch have each targeted distinct user demographics, offering differentiated interactive experiences. Looking ahead, these platforms will increasingly integrate AI technologies and expand globally through offerings like MeRoom.
Daiken Biomedical, a core revenue contributor for the group, continues to grow through its high-quality, effective products and international strategy. The Taiwan Stock Exchange’s approval of its listing affirms the company’s strong operational fundamentals and has been well received by capital markets.
In May, Daiken reported robust revenue growth of NT$157 million, up 67.62% year-over-year. Cumulative revenue for the first five months of 2025 reached NT$614 million, a record high for the same period. The company has announced a first-quarter cash dividend of NT$1.57 per share. Its trial operations in the Japanese market are progressing smoothly, and revenue contributions from Japan are expected to begin in the first half of next year.
Chairman Chia-Ming Chang noted that Sunfun and Daiken will pursue a three-pronged strategy in 2025: revenue growth, capital market advancement, and business integration. Beyond its IPO, Daiken will focus on international expansion in markets such as Japan and Australia, further boosting its market share and competitiveness in the health supplement industry. Simultaneously, Sunfun will continue to advance AI development and beauty-housing related services, reinforce its green sustainability initiatives, and expand into overseas markets, all in pursuit of long-term innovation-driven value creation.
Sunfun emphasized that it remains committed to its dual focus on digital social platforms and the healthcare industry. Through AI integration, cross-industry development, and international market expansion, the company is building a resilient, diversified operational ecosystem. Looking ahead, the group will continue to drive sustainable business growth and enhance shareholder value with innovation at its core.
Resource: 尚凡今年三軌並行 子公司大研生醫上市案獲准
